ESR1 and breast carcinoma: In the context of breast cancer, ORAI3 silencing has anti-proliferative effects on estrogen receptor-α (ERα)-positive MCF-7 cells in vitro and in vivo [28,29], but no effect on the anchorage-independent growth of ERα-negative/basal/triple negative MDA-MB-231 breast cancer cells [29].